NEW YORK ( TheStreet) -- "Mad Money" Research Director Nicole Urken met with TheStreet's Jim Cramer to discuss some powerful cancer-fighting procedures that have begun to emerge.

With the American Society of Clinical Oncology conference wrapping up this week in Chicago, some old-name pharmaceutical stocks are getting a boost for their recent progress on cancer-fighting techniques.

Two names that Cramer and Urken continue to like are Merck ( MRK) and Bristol-Myers ( BMY).

The new PD-1 procedure, which involves using the patient's immune system to target and fight cancerous cells, hasn't seemed to gain much traction until now.

This technique is something that Gilead ( GILD) is looking at, even though the company has been focused on treating HIV and hepatitis C. BioMarin ( BMRN) is also looking at entering the space.

"These are all positive names with long-term drivers," Urken said, adding that they are "also helping improve people's lives and fight disease."

-- Written by Bret Kenwell in Petoskey, Mich.
Bret Kenwell currently writes, blogs and also contributes to Rocco Pendola's Weekly Options Newsletter. Focuses on short- to intermediate-term trading opportunities that can be exposed via options. He prefers to use debit trades on momentum setups and credit trades on support/resistance setups. He also focuses on building long-term wealth by searching for consistent, quality dividend paying companies and long-term growth companies. He considers himself the surfer, not the wave, in relation to the market and himself. He has no allegiance to either the bull side or the bear side.

If you liked this article you might like

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

The Jury Is Still Out on Merck

The Jury Is Still Out on Merck

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Taking Merck's Temperature

Taking Merck's Temperature

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here